ClonaCell™ Media for Hybridoma and CHO Cell Line Development
ClonaCell™ for Hybridoma and Cell Line Development
Liquid and Semi-Solid Media for Efficient Cell Cloning and Generation
Develop ClonaCell™-CHO and ClonaCell™-HY formulations help you achieve a high probability of monoclonality and clonal diversity in just one step.
, , and other cell types using the ClonaCell™ portfolio of innovative cell line-specific media, designed to provide optimal culture conditions. Available in both methylcellulose-based (semi-solid) and liquid form,View all ClonaCell™ media and supplements, and download our brochure to help you choose the right product for your needs.
Use ClonaCell™ to:
- Save time and resources with a proven semi-solid cloning method that overcomes the challenges of traditional limiting dilution cloning
- Nurture and save finicky hybridomas generated from mouse, rat, human, rabbit and hamster cells
- Increase subcloning efficiency during CHO cell line development
Research-stage biotechnology companies and antibodies service companies use ClonaCell™-HY to complete antibody development projects faster and deliver the best antibodies for each application.
Dr. M. Javad Aman, President and CSO, Integrated BioTherapeutics, Inc.
Why Use ClonaCell™?
- Save time with semi-solid cloning. Don’t waste resources on empty cloning wells.
- Superior cloning efficiency and growth of CHO and other cell lines, hybridomas and myelomas.
- Base methylcellulose medium is easily customized for your cell type. Custom formulations, packaging, and additional sizes are available upon request.
- Rigorous performance testing, ensuring lot-to-lot reproducibility.
- Industry-recognized manufacturing expertise and unparalleled technical support.
Try ClonaCell™ in your own lab.
ClonaCell™-HY Hybridoma Kit Media
Scientific Resources
Key Applications
Cell Line Development:
Rodríguez L et al. (2015) Generation of Monoclonal Antibodies Specific of The Postfusion Conformation of The Pneumovirinae Fusion (F) Protein. J Virol Methods.
Young J et al. (2015) A Novel Immunoassay to Measure Total Serum Lymphotoxin-α Levels in The Presence of An Anti-LTα Therapeutic Antibody. J Immunol Methods Epub ahead.
Chronopoulou E et al. (2014) Hybridoma Technology for The Generation of Rodent mAbs via Classical Fusion. In: Ossipow V, N Fischer (Eds.) Monoclonal Antibodies: Methods and Protocols, Methods in Molecular Biology. 2nd Ed. New York: Springer Science+Business Media.: pp47–70.
Date Y et al. (2014) Label-Free Impedimetric Immunoassay for Trace Levels of Polychlorinated Biphenyls in Insulating Oil. Anal Chem 86(6): 2989–2996.
García-Barreno B et al. (2014) Characterization of An Enhanced Antigenic Change in The Pandemic 2009 H1N1 Influenza Virus Haemagglutinin. J Gen Virol 95(PART 5): 1033–1042.
Tan GS et al. (2014) Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets The Fusion Domain of Group 2 Influenza A Virus Hemagglutinin. J Virol 88(23): 13580–13592.
Kelly-Cirino CD & Mantis NJ. (2009) Neutralizing Monoclonal Antibodies Directed Against Defined Linear Epitopes on Domain 4 of Anthrax Protective Antigen. Infect Immun 77(11): 4859–4867.
Weidanz J a et al. (2006) Levels of Specific Peptide-HLA Class I Complex Predicts Tumor Cell Susceptibility to CTL Killing. J Immunol 177(8): 5088–5097.
Hybridoma Development with ClonaCell™ in Different Species:
Cesaro A et al. (2012) An Inflammation Loop Orchestrated by S100A9 and Calprotectin Is Critical for Development of Arthritis. PLoS One 7(9): e45478.
Smith S a. et al. (2012) Persistence of Circulating Memory B Cell Clones with Potential for Dengue Virus Disease Enhancement for Decades following Infection. J Virol 86(5): 2665–2675.
Fang L et al. (2008) Essential Role of TNF Receptor Superfamily 25 (TNFRSF25) in the Development of Allergic Lung Inflammation. J Exp Med 205(5): 1037–1048.
Ulbrandt ND et al. (2006) Isolation and Characterization of Monoclonal Antibodies Which Neutralize Human Metapneumovirus In Vitro and In Vivo. J Virol 80(16): 7799–7806.
Grimaldi JC et al. (1999) Depletion of Eosinophils in Mice through the Use of Antibodies Specific for C-C Chemokine Receptor 3 (CCR3). J Leukoc Biol 65(6): 846–853.
Pharmacology and Drug Discovery:
Retamal M et al. (2014) Epitope Mapping of The 2009 Pandemic and the A/Brisbane/59/2007 Seasonal (H1N1) Influenza Virus Haemagglutinins Using mAbs and Escape Mutants. J Gen Virol 95(Pt_11): 2377–2389.
Hostetter DR et al. (2007) Hip Is A Pro-Survival Substrate of Granzyme B. J Biol Chem 282(38): 27865–27874.
Jin C et al. (2006) Immunoglobulin G Specifically Binding Plant N-glycans with High Affinity Could Be Generated in Rabbits But Not in Mice. Glycobiology 16(4): 349–357.
Kuroki M et al. (2005) Preparation of Human IgG and IgM Monoclonal Antibodies for MK-1/Ep-CAM by Using Human Immunoglobulin Gene-Transferred Mouse and Gene Cloning of Their Variable Regions. Anticancer Res 25(6A): 3733–3739.
Immunology Research:
Fang L et al. (2008) Essential Role of TNF Receptor Superfamily 25 (TNFRSF25) in The Development of Allergic Lung Inflammation. J Exp Med 205(5): 1037–1048.
Matsumoto SC et al. (2006) Retinal Dysfunction in Patients with Chronic Chagas’ Disease Is Associated to Anti-Trypanosoma Cruzi Antibodies That Cross-React with Rhodopsin. FASEB J 21: 1–21.
Cancer Research:
Stern HM et al. (2010) Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab. Clin Cancer Res 16(5): 1587–1596.
Chen Y et al. (2007) Armed Antibodies Targeting The Mucin Repeats of The Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models. Cancer Res 67(10): 4924–4932.
Wittman VP et al. (2006) Antibody Targeting to A Class I MHC-Peptide Epitope Promotes Tumor Cell Death. J Immunol 177(6): 4187–4195.
Contact STEMCELL Technologies
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.